Literature DB >> 21677438

Treatment of hepatitis B virus-associated nephropathy.

Usama Elewa1, Ana Maria Sandri, W Ray Kim, Fernando C Fervenza.   

Abstract

Epidemiological studies have shown a relationship between hepatitis B virus (HBV) infection and development of proteinuria in some patients (most commonly children), with a predominance for male gender and histological findings of membranous nephropathy on renal biopsy. The presence of immune complexes in the kidney suggests an immune complex basis for the disease, but a direct relation between HBV and membranous nephropathy (or other types of glomerular diseases) remains to be proven. Clearance of HBV antigens, either spontaneous or following antiviral treatments results in improvement in proteinuria. Thus, prompt recognition and specific antiviral treatment are critical in managing patients with HBV and renal involvement. The present review focuses on treatment of HBV with special emphasis given to antiviral therapies, its complications, and dosing in patients with HBV-associated kidney disease.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677438     DOI: 10.1159/000324652

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  15 in total

1.  A case of anti-GBM glomerulonephritis superimposed on HBV-associated membranous nephropathy.

Authors:  Takeshi Yamamoto; Susumu Oseto; Natsuko Imakita; Masami Inada; Megumu Fukunaga
Journal:  CEN Case Rep       Date:  2013-04-13

Review 2.  Viral-Associated GN: Hepatitis B and Other Viral Infections.

Authors:  Warren L Kupin
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 8.237

3.  Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.

Authors:  Li-Jing Sun; Jian-Ping Shan; Ruo-Lan Cui; Wei-Jie Yuan; Geng-Ru Jiang
Journal:  Int Urol Nephrol       Date:  2017-03-10       Impact factor: 2.370

Review 4.  Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Bruno Sangro; Stephen L Chan; Tim Meyer; María Reig; Anthony El-Khoueiry; Peter R Galle
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

5.  A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy.

Authors:  Yue Yang; Ye-Ping Ma; Da-Peng Chen; Li Zhuo; Wen-Ge Li
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

6.  Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy.

Authors:  Te-Fu Lin; Ping-I Hsu; Kung-Hung Lin; Feng-Woei Tsay; Tzung-Jiun Tsai; Yan-Hua Chen; Hsien-Chung Yu
Journal:  Gastroenterol Res Pract       Date:  2017-07-05       Impact factor: 2.260

Review 7.  Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

8.  Collapsing glomerulopathy associated with hepatitis B infection: A case report.

Authors:  M Mantan; R Grover; S Kaur; V Batra
Journal:  Indian J Nephrol       Date:  2016 Jul-Aug

9.  HBV-Associated Postinfectious Acute Glomerulonephritis: A Report of 10 Cases.

Authors:  Yong Zhang; Junxia Li; Weihua Peng; Guoqing Yu; Liping Wang; Jian Chen; Feng Zheng
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

10.  Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy.

Authors:  Lena Berchtold; Gilbert Zanetta; Karine Dahan; Fabrice Mihout; Julie Peltier; Dominique Guerrot; Isabelle Brochériou; Pierre Ronco; Hanna Debiec
Journal:  Kidney Int Rep       Date:  2017-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.